Glucocorticoid-induced myopathy in people with asthma: a systematic review

Wu, Kenneth K.; Michalski, Anna; Cortes, Daniel; Rozenberg, Dmitry; Mathur, Sunita

doi:10.1080/02770903.2021.1926488

Cited by 7 publications

(3 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The manifestations of DIMs range from mild myalgia to chronic disease with myasthenia gravis and rhabdomyolysis with acute renal failure, which may lead to death in severe cases [1,2]. More than 150 drugs can cause DIM, among which the most famous include statins and long-term high-dose glucocorticoids [3][4][5][6]. The pathogenesis of DIM has not been clearly defined, and it is generally believed that the mechanisms include direct myotoxicity (e.g., statins and chloroquine), immune-mediated myopathy (e.g., checkpoint inhibitors and statins), and indirect muscle damage (e.g., diuretic-associated hypokalemia) [7,8].…”

Section: Introductionmentioning

confidence: 99%

Reporting of Drug-Induced Myopathies Associated with the Combination of Statins and Daptomycin: A Disproportionality Analysis Using the US Food and Drug Administration Adverse Event Reporting System

Wei

Yin

et al. 2023

JCM

View full text Add to dashboard Cite

Background: Myopathy is one of the most common adverse reactions of daptomycin and statins. We aimed to evaluate the muscular toxicity of the combination therapy of daptomycin and statins in a large pharmacovigilance database. Methods: This was a retrospective disproportionality analysis based on real-world data. All cases reported between the first quarter of 2004 and the fourth quarter of 2022 where daptomycin and statins were reported were gathered from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. Disproportionality analyses were conducted by estimating the proportional reporting ratios (PRRs), reporting odds ratio (ROR), and information component (IC). Results: A total of 971,861 eligible cases were collected from the FAERS database. Data analysis showed that rosuvastatin (ROR: 124.39, 95% CI: 87.35–178.47), atorvastatin (ROR: 68.53, 95% CI: 51.93–90.43), and simvastatin (ROR: 94.83, 95% CI: 71.12–126.46) combined with daptomycin increased the reporting frequency of myopathy. Moreover, myopathy was reported more frequently with the 3-drug combination (ROR: 598.01, 95% CI: 231.81–1542.71). For rhabdomyolysis, the frequency of reports also increased when daptomycin was combined with rosuvastatin (ROR: 156.34, 95% CI: 96.21–254.05), simvastatin (ROR: 72.65, 95% CI: 47.36–111.44), and atorvastatin (ROR: 66.31, 95% CI: 44.06–99.81). Conclusions: The combination of daptomycin and statins increased the association of myopathy and rhabdomyolysis, especially with rosuvastatin, simvastatin, and atorvastatin.

show abstract

Section: Introductionmentioning

confidence: 99%

Reporting of Drug-Induced Myopathies Associated with the Combination of Statins and Daptomycin: A Disproportionality Analysis Using the US Food and Drug Administration Adverse Event Reporting System

Wei

Yin

et al. 2023

JCM

View full text Add to dashboard Cite

show abstract

“…As one kind of chronic inflammatory disease of the airway, asthma is still regarded as a great medical and socioeconomic burden worldwide ( Barberand et al, 2021 ; Klimek et al, 2021 ). In the past decades, asthma treatment is mainly through the inhalation or systemic administration of bronchodilators and anti-inflammatory agents, such as glucocorticoids ( Wu et al, 2021 ). However, it presents major challenges in drug delivery and therapeutic efficacy due to the mucus obstruction in airway inflammation diseases; thus, the pathological symptoms cannot be controlled even with high doses of the recommended drugs ( Chakraborty et al, 2021 ).…”

Section: Introductionmentioning

confidence: 99%

Berberine-Loaded Biomimetic Nanoparticles Attenuate Inflammation of Experimental Allergic Asthma via Enhancing IL-12 Expression

Jin

Zhang

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Asthma is one of the most common chronic pulmonary disorders, affecting more than 330 million people worldwide. Unfortunately, there are still no specific treatments for asthma so far. Therefore, it is very important to develop effective therapeutics and medicines to deal with this intractable disease. Berberine (Ber) has fabulous anti-inflammatory and antibacterial effects, while its low water solubility and bioavailability greatly limit its curative efficiency. To improve the nasal mucosa absorption of poorly water-soluble drugs, such as Ber, we developed a platelet membrane- (PM-) coated nanoparticle (NP) system (PM@Ber-NPs) for targeted delivery of berberine to the inflammatory lungs. In vivo, PM@Ber-NPs exhibited enhanced targeting retention in the inflammatory lungs compared with free Ber. In a mouse model of house dust mite- (HDM-) induced asthma, PM@Ber-NPs markedly inhibited lung inflammation, as evident by reduced inflammatory cells and inflammatory cytokines in the lung compared with free Ber. Collectively, our study demonstrated the inhibitory actions of nasally delivered nanomedicines on HDM-induced asthma, primarily through regulating Th1/Th2 balance by enhancing IL-12 expression which could potentially reduce lung inflammation and allergic asthma.

show abstract

“…As one kind of chronic inflammatory disease of the airway, asthma is still regarded as a great medical and socioeconomic burden worldwide (Barberand et al, 2021;Klimek et al, 2021). In the past decades, asthma treatment is mainly through the inhalation or systemic administration of bronchodilators and anti-inflammatory agents, such as glucocorticoids (Wu et al, 2021). However, it presents major challenges in drug delivery and therapeutic efficacy due to the mucus obstruction in airway inflammation diseases; thus, the pathological symptoms cannot be controlled even with high doses of the recommended drugs (Chakraborty et al, 2021).…”

Section: Introductionmentioning

confidence: 99%

Image1.jpg

View full text Add to dashboard Cite

Glucocorticoid-induced myopathy in people with asthma: a systematic review

Cited by 7 publications

References 55 publications

Reporting of Drug-Induced Myopathies Associated with the Combination of Statins and Daptomycin: A Disproportionality Analysis Using the US Food and Drug Administration Adverse Event Reporting System

Reporting of Drug-Induced Myopathies Associated with the Combination of Statins and Daptomycin: A Disproportionality Analysis Using the US Food and Drug Administration Adverse Event Reporting System

Berberine-Loaded Biomimetic Nanoparticles Attenuate Inflammation of Experimental Allergic Asthma via Enhancing IL-12 Expression

Image1.jpg

Contact Info

Product

Resources

About